[1] ZHENG Yuling ZHANG Yaling,.Interpretation of Expert Consensus on Treatment Scheme of Esophageal Cancer with Integrated Traditional Chinese and Western Medicine (2021 Edition) [J]. Modern Traditional Chinese Medicine, 2021, (06): 11-15. [doi: 10.13424/j.cnki.mtcm.2021.06.003]
Interpretation of Expert Consensus on Treatment Scheme
of Esophageal Cancer with Integrated Traditional
Chinese and Western Medicine (2021 Edition)
- Article number:
- 1672-0571(2021)06-0011-05
- Keywords:
- Key words:Esophageal cancer; Integrated traditional Chinese and Western medicine; Expert consensus; Interpretation
- ZTFLH:
- R735.1
- Code:
- A
- Abstract:
- Abstract：Esophageal cancer is one of the common malignant gastrointestinal tumors in China.It is a key disease in tumor clinical work.In order to standardize the treatment of esophageal cancer in China，the Chinese society of integrated traditional Chinese and Western medicine has written the expert consensus on the treatment scheme of integrated traditional Chinese and Western medicine for esophageal cancer (2021 Edition) (hereinafter referred to as the consensus) according to different stages of occurrence and development of esophageal cancer.This paper interprets the relevant key contents of the consensus in order to deepen the medical workers’understanding of the consensus and promote the standardized treatment of esophageal cancer with integrated traditional Chinese and Western medicine.
References:
［1］王悠清编译,Sung H,Ferlay J,等.2020年全球癌症统计报告[J].中华预防医学杂志,2021,55(3):398.
［2］郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤情况分析[J].中华肿瘤杂志,2019，(1):19-28.
［3］国家卫生健康委员会.食管癌诊疗规范(2018年版)\[J].中华消化病与影像杂志(电子版),2019,9(4):158-192.
［4］国家消化内镜专业质控中心,国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,等.中国早期食管癌及癌前病变筛查专家共识意见(2019年,新乡)[J].中华健康管理学杂志，2019,13(6):465-473.
［5］Zhao X，Lim F.Lifestyle Risk Factors in Esophageal Cancer：An Integrative Review[J].Critical care nursing quarterly,2020,43(1):86-98.
［6］闫二帅,赵宝生,刘尚国,等.遗传因素在豫北地区食管癌中的作用分析[J].现代肿瘤医学,2018,26(21):3418-3421.
［7］贾立群,段锦龙,邓博,等.舌诊在食管癌及癌前病变筛查中的应用探索[A]∥中国中西医结合学会肿瘤专业委员会.第十五届全国中西医结合肿瘤学术大会论文集[C].中国中西医结合学会肿瘤专业委员会:中国中西医结合学会,2017:2.
［8］段锦龙.食管癌高危人群舌象特征分析与应用探索[D].北京：北京中医药大学,2016.
［9］刘思达.四川省盐亭县食管癌高危人群舌象特征及相关危险因素分析[D].北京：北京中医药大学,2018.
［10］李妍妍.郑玉玲教授以“治未病”思想论治食管癌经验[J].中医研究,2011,24(5):67-69.
［11］郑玉玲,陈玉龙.中医药治疗食管癌研究述评[J].中医肿瘤学杂志,2020,2(3):1-4.
［12］关茜，焦俊喆，叶子豪，等.益脾扶正方联合化疗治疗中晚期食管癌21例[J].陕西中医药大学学报，2019,42(1):150-158.
［13］武兴娣,张清清,李莉娜,等.中医药结合放疗治疗食管癌及机制的研究进展[J].中国肿瘤临床,2018,45(16):859-862.
［14］朱芮,完家进,杨联河.中医药联合放疗治疗食管癌研究进展[J].光明中医,2018,33(19):2820-2822.
［15］李善君.口服中药干预食管癌化疗的系统评价及meta分析[D].北京：北京中医药大学,2018.
［16］王宝仪,邓超,邓博,等.温络通外用联合甲钴胺治疗紫杉醇所致周围神经毒性的疗效观察[J].中日友好医院学报,2020,34(2):79-82.
［17］Yu Ran,Wu Xuefeng,Jia Liqun,et al.Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome：A Randomized，Double-Blind，and Parallel-Controlled Trial[J].Integrative Cancer Therapies,2020,19.
［18］文清.芪术方泡洗治疗氟尿嘧啶类药物引起手足综合征的临床观察[D].长沙：湖南中医药大学,2019.
［19］Deng Bo,Jia Liqun,Tan Huangying，et al.Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms[J].Journal of Traditional Chinese Medicine,2017,37(1):35-42.
［20］吴梦雨,邓博,贾立群.生姜泻心汤对CT26荷瘤小鼠伊立替康相关毒性的防治作用研究[J].中日友好医院学报,2018,32(6):356-359,377,320.
［21］王珏,陈朝辉.化疗所致造血干细胞衰老的相关信号通路及中药治疗进展[J].中医药学报,2019,47(3):118-121.
［22］翟韵怡,高静东.化疗后骨髓抑制的中医治疗研究进展[J].中医临床研究,2021,13(6):67-71.
［23］吴怡,张云玲,孟严琴.中药穴位贴敷联合常规护理干预肿瘤化疗后便秘临床研究[J].新中医,2020,52(13):163-165.
［24］Kato H,Nakajima M.Treatments for esophageal cancer:a review[J].Gen Thorac Cardiovasc Surg,2013,61(6):330-335.
［25］杜清华,王仁生.放射性口腔黏膜炎的发病过程[J].国际肿瘤学杂志,2011,4(6):465-467.
［26］陆叶,沈红梅.放射性口腔炎的治疗进展[J].临床与病理杂志,2017,37(6):1269-1275.
［27］许彦超,刘亚南,李吉磊,等.中医外治法治疗食管癌评述[J].中医学报,2020,35(8):1681-1684.
［28］范青.痛块消乳膏外治癌性躯体痛的临床研究[D\].北京：北京中医药大学,2012.
［29］周民涛,李毓,韩学昌,等.电针对胸科手术后镇痛的临床研究[J].中国针灸,2017,37(7):705-709.
［30］于盼,韩建宏,田建辉.中医药治疗肺癌恶性胸腔积液研究进展[J].西部中医药,2021,34(5):152-155.
［31］周明慧,蔺婷婷.自我效能干预对肺癌患者疲乏、睡眠障碍及生存质量的影响[J].长治医学院学报,2020,34(3):231-235.
［32］曹旭,甘蕾,王勇飞,等.四逆加人参汤治疗癌因性疲乏临床观察[J/OL].中华中医药学刊:(2021-06-08)\[2021-0722\].http://kns.cnki.net/kcms/detail/21.1546.r.20210607.1441.002.html.